Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure.

ABSTRACT:

Background

Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed.

Objective

Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients.

Methods

We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertil

SUBMITTER: Huynh TLT 

PROVIDER: S-EPMC11610471 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature